The future is now? Clinical and translational aspects of “Omics” technologies

Abstract

Big data has become a central part of medical research, as well as modern life generally. “Omics” technologies include genomics, proteomics, microbiomics and increasingly other omics. These have been driven by rapid advances in laboratory techniques and equipment. Crucially, improved information handling capabilities have allowed concepts such as artificial intelligence and machine learning to enter the research world. The COVID‐19 pandemic has shown how quickly information can be generated and analyzed using such approaches, but also showed its limitations. This review will look at how “omics” has begun to be translated into clinical practice. While there appears almost limitless potential in using big data for “precision” or “personalized” medicine, the reality is that this remains largely aspirational. Oncology is the only field of medicine that is widely adopting such technologies, and even in this field uptake is irregular. There are practical and ethical reasons for this lack of translation of increasingly affordable techniques into the clinic. Undoubtedly, there will be increasing use of large data sets from traditional (e.g. tumor samples, patient genomics) and nontraditional (e.g. smartphone) sources. It is perhaps the greatest challenge of the health‐care sector over the coming decade to integrate these resources in an effective, practical and ethical way.

SOX Transcription Factors as Important Regulators of Neuronal and Glial Differentiation During Nervous System Development and Adult Neurogenesis

“…In the past decade, the "omics" technologies, such as genomics, transcriptomics, miRNomics, and proteomics have become integrated parts of the research in biology and medicine, enabling progress in collecting, processing and integrating huge amounts of health-related information (D'Adamo et al, 2020).…”

Liquid biopsies and cancer omics

“…The scientific community moved from a purely histopathologic cancer diagnosis to a molecular-based one, allowing clinicians to develop more accurate and complex prognostic scores, as well as to select better treatment options according to the mutational background of a given neoplasm (as in the case of EGFR or ALK mutations in lung cancer 2 , or the V600E mutation of BRAF in either colorectal cancer 3 or melanoma, as prominent examples). This approach opened the era of targeted therapies and, to some extent, to precision medicine [4][5][6] . "Intelligent drugs" designed to specifically target a precise molecular objective, have entered the clinics alongside classic chemotherapy or substituting it 7 .…”

A Web Screening on Training Initiatives in Cancer Genomics for Healthcare Professionals

“…The technological innovations of genomics and other omics sciences allow physicians to offer personalized diagnosis and treatments, especially in the oncology field [ 120 , 121 , 122 ]. Through personalized medicine based on genomics, it has been possible to achieve an improvement in risk stratification, for example, in hereditary breast cancer.…”